SermorelinCheck methods and identity
Why a urine test measures both sermorelin and a breakdown product
2 numbered sourcesSource years 2013, 2025
Peptides are short amino-acid chains linked by peptide bonds. A peptide can act as a signal, and enzymes can split its bonds after it enters the body. Sermorelin is the synthetic, amidated version of the first 29 residues of human growth hormone–releasing hormone (GHRH). An analytical study asked how to distinguish this peptide and a breakdown product from related substances in urine. [1, 2]
No newer primary study of this exact analytical method was identified. The paper first appeared online in October 2025, before appearing in a January 2026 journal issue. The researchers developed and validated a technique that separates compounds in urine samples and measures their masses and characteristic fragments. They included sermorelin and its main metabolite, along with other GHRH-related molecules such as tesamorelin. A metabolite is a substance produced as the original compound is changed or broken down. [1]
The study examined features such as detection limits, limits of identification and how the sample itself could affect the reading. Detecting a signal at a low concentration and assigning the signal to a particular molecule are related tasks with different requirements. Including a metabolite in the test also gives a laboratory an additional target when the intact molecule is hard to measure. [1]
The experiment validated an analytical method in urine. It did not establish how long sermorelin remains active in a person or whether a particular clinical outcome follows exposure. The ability to find an intact peptide or its fragments gives information about the contents of a sample. It cannot determine the response of the pituitary or replace an effectiveness study. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Uçaktürk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis (publication 2025-10-20). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
- 2.U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (publication 2013-03-04). (opens in a new tab)
govinfo.gov↩ Back to text
